Tenon Medical, Inc.

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

TNON$1.74-0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Convertible Preferred Stock and Stockholders’ Equity

Condensed Statements of Convertible Preferred Stock and Stockholders’ Equity (Unaudited)

(In thousands, except share data)

Three months ended September 30, 2025 and 2024:

Series A Convertible Preferred Stock · Series B Convertible Preferred Stock · Common Stock · Additional Paid-In · Accumulated
	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Deficit	Total
Balance at June 30, 2025	256,968	$3,300	86,454	$452	7,592,217	$8	$78,084	$(75,131)	$6,713
Stock-based compensation expense	—	—	—	—	—	—	58	—	58
Shares issued for acquisition of assets of SiVantage, Inc.	—	—	—	—	710,300	1	1,365	—	1,366
Issuance of common stock upon conversion of Series A convertible preferred stock	(52,809)	(678)	—	—	300,005	—	678	—	—
Release of restricted stock units	—	—	—	—	2,986	—	—	—	—
Net loss	—	—	—	—	—	—	—	(3,339)	(3,339)
Balance at September 30, 2025	204,159	$2,622	86,454	$452	8,605,508	$9	$80,185	$(78,470)	$4,798
Balance at June 30, 2024	256,968	$3,300	—	—	472,604	—	60,007	(62,475)	$832
Stock-based compensation expense	—	—	—	—	—	—	910	—	910
Issuance of Series B preferred stock and warrants, net of issuance costs	—	—	86,454	452	—	—	37	—	489
Issuance of common stock, prefunded warrants, and warrants, net of issuance costs	—	—	—	—	55,000	—	3,826	—	3,862
Issuance of common stock upon exercise of prefunded warrants	—	—	—	—	1,167,850	1	(1)	—	—
Issuance of common stock and warrants under inducement agreement	—	—	—	—	1,222,850	1	4,305	—	4,306
Issuance of common stock upon exercise of warrants	—	—	—	—	32,266	—	812	—	812
Issuance of common stock, net of issuance cost	—	—	—	—	37,618	—	164	—	164
Issuance of common stock for reverse stock split	—	—	—	—	147,825	1	(1)	—	—
Net loss	—	—	—	—	—	—	—	(3,184)	(3,184)
Balance at September 30, 2024	256,968	$3,300	86,454	$452	3,136,013	$3	$70,095	$(65,659)	$8,191

Nine months ended September 30, 2025 and 2024:

Series A Convertible Preferred Stock · Series B Convertible Preferred Stock · Common Stock · Additional Paid-In · Accumulated · Accumulated Other Comprehensive
	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Deficit	Loss	Total
Balance at December 31, 2024	256,968	$3,300	86,454	$452	3,138,804	$3	$70,962	$(68,746)	$—	$5,971
Stock-based compensation expense	—	—	—	—	—	—	1,347	—	—	1,347
Issuance of common stock, pre-funded warrants and warrants under inducement agreement, net of issuance costs	—	—	—	—	2,445,700	3	2,732	—	—	2,735
Issuance of common stock, prefunded warrants, and warrants, net of issuance costs	—	—	—	—	2,005,000	2	3,522	—	—	3,524
Shares issued for acquisition of assets of SiVantage, Inc.	—	—	—	—	710,300	1	1,365	—	—	1,366
Issuance of common stock upon conversion of Series A convertible preferred stock	(52,809)	(678)	—	—	300,005		678	—	—	—
Release of restricted stock units	—	—	—	—	5,699	—	—	—	—	—
Deferred financing costs	—	—	—	—	—	—	(421)	—	—	(421)
Net loss	—	—	—	—	—	—	—	(9,724)	—	(9,724)
Balance at September 30, 2025	204,159	$2,622	86,454	$452	8,605,508	$9	$80,185	$(78,470)	$—	$4,798
Balance at December 31, 2023	—	$—	—	$—	325,039	$—	$55,897	$(55,073)	$(46)	$778
Stock-based compensation expense	—	—	—	—	—	—	2,962	—	—	2,962
Issuance of Series A preferred stock and warrants, net of issuance costs	256,968	3,300	—	—	—	—	254	—	—	3,554
Issuance of Series B preferred stock and warrants, net of issuance costs	—	—	86,454	452	—	—	37	—	—	489
Issuance of common stock, prefunded warrants, and warrants, net of issuance costs	—	—	—	—	55,000	—	3,862	—	—	3,862
Issuance of common stock upon exercise of prefunded warrants	—	—	—	—	1,167,850	1	(1)	—	—	—
Issuance of common stock and warrants under inducement agreement	—	—	—	—	1,222,850	1	4,305	—	—	4,306
Issuance of common stock upon exercise of warrants	—	—	—	—	32,266	—	812	—	—	812
Issuance of common stock, net of issuance costs	—	—	—	—	178,048	—	1,968	—	—	1,968
Release of restricted stock units	—	—	—	—	7,135	—	—	—	—	—
Issuance of common stock for reverse stock split	—	—	—	—	147,825	1	(1)	—	—	—
Other comprehensive income	—	—	—	—	—	—	—	—	46	46
Net loss	—	—	—	—	—	—	—	(10,586)	—	(10,586)
Balance at September 30, 2024	256,968	$3,300	86,454	$452	3,136,013	$3	$70,095	$(65,659)	$—	$8,191

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.